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Introduction
Sepsis is a leading cause of death in critically ill patients; 
the mortality in patients admitted to intensive care units 
and given both antibiotics and supportive care varies 
from 20% up to more than 60% [1,2]. Th e problem is 
becoming even more prominent because the frequency 
of sepsis is increasing due to the prevalence of antibiotic-
resistant pathogens [3]. Historically the widely accepted 
hypothesis was that sepsis was in fact an uncontrolled 
infl am matory response. Accordingly, the organism is 
killing itself while the pathogens are considered as by-
standers [4,5]. However, this theory was based on animal 
studies that do not refl ect the clinical picture in humans 
[6]. Studies on animal models usually involve the appli-
cation of large doses of endotoxin or pathogens, leading 
to much higher levels of circulating cytokines in 
com pari son to humans with sepsis and ending in death by 
‘cytokine storm’ [6]. Recent data indicate that the immune 
system during sepsis actually shows two phases: an initial 
hyper-infl ammatory stage followed by a pro longed hypo-
infl ammatory phase [7]. In addition, numerous studies 
and trials have shown that the application of anti-
infl ammatory agents is futile, or can even worsen chances 
of survival [7,8]. Th ere are some exceptions, however. For 
example, Annane and co-workers [9] have shown that the 
application of selected corticosteroids at moderate doses 
may decrease the mortality of sepsis. In contrast to 
prevalently disappointing results for anti-infl ammatory 
therapies, a pro-infl ammatory approach seems to be more 
promising. For example, interferon-γ, a potent macro-
phage activator, improved survival of patients with sepsis 
[10]. IL-12, an immune stimulant, reduced mortality 
from subsequent sepsis when administered after burn 
injury [11]. Pertinent to these data, Hotchkiss and Karl 
[7] have recently proposed a coherent immunological 
approach in sepsis treatment, consisting of moderate 
suppression of the immune system during the hyper-
infl ammatory mode in early sepsis and intensive promo-
tion of activity of the immune system during the hypo-
infl ammatory phase.
Immunohistochemical analysis has shown that in the 
majority of patients with sepsis, only lymphocytes and 
gastrointestinal epithelial cells die [12]. Th ese two types 
of cells normally undergo rapid turnover through 
apoptosis, and sepsis most likely accelerates this process. 
Cell death in the heart, lungs and kidneys has been 
observed to be minor, resulting in insignifi cant damage 
to these organs [13]. Studies in patients with acute renal 
failure have illustrated discordance between the level of 
renal dysfunction and the degree of tubular necrosis [14]. 
It is very interesting that most sepsis survivors who 
showed renal failure recover baseline renal function [15], 
suggesting that changes that may cause death are in fact 
reversible. It can be concluded that organ failure in sepsis 
is not provoked by tissue damage, but instead by the 
dysfunction of a substantial number of cells. A central 
paradigm in organ dysfunction is the concept of tissue 
hypoxia; the failure to adequately supply organs with 
oxygen [16]. However, non-survivors of sepsis exhibit an 
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impaired capacity to increase tissue oxygen consumption 
in response to the augmentation of oxygen delivery [17]. 
Th is is reinforced by the fact that well-perfused endo-
toxaemic model animals still present acidosis [18]. In line 
with these facts, Fink [19] has postulated that impaired 
cellular O2 utilisation, rather than inadequate oxygen 
delivery, may play an important role in sepsis develop-
ment. As mitochondria represent the main consumers of 
O2, signifi cant attention has been focused on the role of 
mitochondrial dysfunction in sepsis [20]. Brealey and co-
workers [21] demonstrated that there is an association 
between mortality in sepsis and mitochondrial dysfunc-
tion. In addition, a decrease in the number of mitochon-
dria has been observed in patients with prolonged septic 
conditions [22], implying that sepsis-related dysfunction 
of mitochondria may result in mitoptosis. Th e direct 
consequence of mitochondrial dysfunction is a signifi cant 
fall in the level of ATP, as observed in the tissues of model 
animals and septic patients [21].
An activated immune system and dysfunctional mito-
chondria represent the two most potent sources of 
reactive molecular species in organisms [23]. Pertinent to 
this, it has been documented that sepsis is characterised 
by excessive production of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS), both in the circu-
lation (by activated immune system cells and endothelial 
cells) and in the aff ected organs (by dysfunctional 
mitochondria and due to a modifi ed anti-oxidative 
status) [16,24]. Many authors agree that ROS and RNS 
(Table  1) play a crucial role in the pathophysiology of 
sepsis [24-26]. Some of these species interfere with 
signalling cascades, while others provoke deleterious 
eff ects on various biological molecules and structures. It 
is clear that the increased production of signalling species 
(for example, nitric oxide (•NO) and hydrogen peroxide 
(H2O2)) and strong oxidants (the hydroxyl radical (•OH) 
and hypochlorous acid (HOCl)) act in synergy with 
collapse in energy metabolism to provoke cell dysfunc-
tion, which may result in organ failure and death.
When considering possible treatment strategies for 
sepsis patients, it is crucial to identify the main events in 
the development of sepsis and the schedule of changes of 
pathogenic factors. In the present review we focus on 
redox mechanisms of sepsis without under-estimating 
any other possible contributors to this pathology. We 
outline the most probable sequence of redox events 
leading to cellular dysfunction in sepsis. In addition, the 
current potential of and prospects for the application of 
redox therapy in sepsis are discussed.
The chain of redox events
Oxidative burst
A plasma oxidative burst takes place early in sepsis orches-
trated by neutrophils, macrophages and endothe lial cells 
[27]. Th ese cells represent the innate immune system, our 
fi rst line of defence against invading micro organisms. 
Accordingly, they are equipped with diff erent ROS and 
RNS [23]. When activated by pathogens they generate 
superoxide (•O2-), H2O2, •NO and HOCl, while •OH, per-
oxynitrite (ONOO-), the nitrogen dioxide radical (•NO2), 
the hydroperoxyl radical (•OOH), and the peroxyl radical 
(•ROO) are produced in secondary reactions (Figure 1). 
Th e lack of this intrinsic oxidant system can be deleter-
ious to the host as demonstrated in subjects lacking •O2- 
generation. Mice defi cient in NADPH oxidase subunits 
and humans with chronic granulo ma tous disease who 
also lack NADPH oxidase activity are incapable of 
adequately performing bactericidal func tions [28,29]. 
However, the oxidant system may also signifi cantly 
modify redox settings in the organism.
Septic plasma shows a number of positive markers of 
oxidative stress (Table 2). Anti-oxidants scavenge reactive 
species, which leads to a decrease in the concentration of 
anti-oxidants. Th e level of free thiols decreases due to 
oxidation or nitrosylation. As a result, the total anti-oxi-
dant capacity of plasma is reduced. In addition, un-
charged radicals attack membranes, initiating a lipid 
peroxidation chain reaction (Figure 1, reactions 6 to 8). 
Interestingly, two research groups have reported that the 
plasma total anti-oxidant capacity in sepsis is initially 
decreased but increases over time as the condition 
progresses [30,31]. Th is indicates that the redox status of 
plasma during sepsis follows a two-phase pattern charac-
teristic of the immune system.
It is important to note that redox conditions in the 
plasma of neonates with sepsis seem to be diff erent in 
comparison to other patient groups. Cherian and 
colleagues [32] reported that there were no signifi cant 
changes in the levels of ascorbate, glutathione and 
oxidative stress biomarkers in the blood of neonates and 
babies with sepsis when compared to age-matched 
controls. Th is may be attributed to the immaturity of the 
immune system. Neonates have a low neutrophil pool 
and reduced release of pro-infl ammatory cytokines (for 
Table 1. The main reactive species implicated in the 
pathogenesis of sepsis
Free radicals Non-radicals
Reactive oxygen species 
Superoxide, •O2
- Hydrogen peroxide, H2O2
Hydroxyl radical, •OH Hypochlorous acid, HOCl
Hydroperoxyl radical, •OOH 
Peroxyl radical, •ROO 
 
Reactive nitrogen species 
Nitric oxide, •NO Peroxynitrite, ONOO-
Nitrogen dioxide radical, •NO2 Peroxynitrous acid, ONOOH
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example, TNF-α), and their neutrophils have an impaired 
capacity to migrate to sites of infection, which may 
account for the less prominent oxidative burst in 
response to infection [33]. Fortunately, neonatal sepsis is 
very uncommon and shows a relatively low mortality rate 
of 5 to 10% (in developed countries) [34]. Th e pre sented 
facts regarding neonatal sepsis strongly imply that 
pronounced immune system-mediated redox changes 
may play an important role in sepsis initiation in adults.
Modifi ed redox status of septic plasma aff ects the 
intracellular milieu of surrounding tissues due to: (i) the 
capability of some reactive species, such as H2O2, •NO, 
and HOCl, to cross cellular membrane [23,35]; (ii) oxida-
tive changes in the membrane (Figure 1, reactions 6 to 8) 
[36]; and (iii) the activation of specifi c receptors. After 
entering the cell, H2O2 and •NO participate in secondary 
reactions (Figure 1, reactions 1 to 4) to pro duce more 
reactive species, which provoke intracellular oxidative 
stress. Due to its high reactivity with bio molecules, HOCl 
is predicted to have a very limited diff usion radius in bio-
logical systems [37,38]. Th erefore, only a small fraction of 
HOCl manages to enter the cell, where it may provoke 
protein, DNA, lipid and mito chondria damage [38]. On 
the other hand, H2O2 and •NO represent signalling mole-
cules crucial for normal cell function [39]. Th ey activate 
specifi c sets of genes via a number of transcription 
factors at the nuclear level, of which NF-κB appears to 
have a central role in sepsis [40]. Other factors, such as 
nuclear factor E2-related factor 2 (Nrf2), may also be 
Figure 1. Key redox reactions in living systems [23]. (1) Fenton 
reaction; (6) to (8) lipid peroxidation (ROOH) chain reactions.
ROO + Lipid            ROOH +     CH   
OH  or  OOH + Lipid                    CH    
ONOO- + H+             ONOOH             OH + NO2
O2- + NO              ONOO-  
HOCl + O2-                OH + O2 + Cl- 
Fe2+ + H2O2                Fe3+ + OH- + OH 
     CH     + O2                ROO 
O2- + H+                OOH 
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
Table 2. Redox characteristics of plasma in adults with sepsis
  Patient groups  Method Reference
Anti-oxidant    
 Ascorbate (mg/L) Control: 1.71 ± 0.46 Sepsis: 0.55 ± 0.28 Spectrophotometric  [116]
    assay
  Control: 4.5 to 12 Critically injured: 1.1 ± 0.3 HPLC [117]
 Retinol (μg/L) Control: 735 ± 183 Septic shock: 265 ± 193 HPLC [118]
 Tocopherol (mg/L) Control: 11.5 ± 1.3 Septic shock: 3.6 ± 2.0 HPLC [118]
 β-Carotene (μg/L) Control: 619 ± 259 Septic shock: <101 HPLC [118]
 Lycopene (μg/L) Control: 522 ± 184 Septic shock: <154 HPLC [118]
    
Oxidative stress biomarkers    
 Total plasma thiols (R-SH) (μmol/L) Control: 364 ± 22 Sepsis: 138 ± 14 Ellman’s method [119]
 Lipid peroxidation (μmol/L) Control: <2 Patients with >3 failing organs: 4.9 ± 2.3 TBARS assay [118]
  Control: 0.92 ± 0.39 Sepsis survivors: 0.99 ± 0.14 TBARS assay [120]
   Sepsis non-survivors: 3.33 ± 2.29  
 Lipid peroxidation (nmol/mg of protein) Sepsis (day 1): 2.4 Sepsis (day 7): 2.9 FOX assay [121]
 Total anti-oxidant capacity  Sepsis (day 1): 1.5 Sepsis (day 7): 1.1 ABTS assay [121]
 (nmol/mg of protein)a
 Total anti-oxidant capacity (%) Control: 57.3 to 60.3 Survivors: 51.4 to 55.4 ABTS assay [30]
   Non-survivors: 46.1 to 47.6  
 Total anti-oxidant capacity (μmol/L) Control: 354 ± 9 Sepsis: 265 ± 32 TRAP assay [31]
   Septic shock: 452 ± 34  
aThe use of total anti-oxidant capacity assays is associated with some pitfalls; therefore, the results obtained with such methods should be taken with some caution. 
For example, urate interferes with both the ABTS and the TRAP assays, potentially leading to falsely high values [23]. Urate increases in many pathophysiological 
conditions, for example, in renal failure, which may develop in sepsis. Another problem is that plasma contains a complex mixture of anti-oxidants that react at 
diff erent rates, so some of them may not be detected by rapid assays [23]. ABTS, 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid); FOX, ferrous oxidation-xylenol 
orange; HPLC, high-performance liquid chromatography; TBARS, thiobarbituric acid reactive substances; TRAP, total radical-trapping antioxidant potential.
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involved. Nrf2 is a transcription factor that regulates anti-
oxidant response element (ARE)-mediated transcription 
of a plethora of anti-oxidant and protective genes to 
counteract the harmful eff ects of ROS or environmental 
carcinogens. Non-carcinogenic ARE inducers from a 
variety of chemical classes have been identifi ed to 
enhance the transcriptional activity of Nrf2 through 
S-alkylation of reactive cysteines within the cellular 
redox sensor protein Keap1 (Kelch-like ECH associated 
protein 1) [41]. Following dissociation from the cytosolic 
protein Keap1, a scaff olding protein that binds Nrf2 and 
Cul3 ubiquitin ligase for proteasome degradation, Nrf2 
rapidly accumulates in the nucleus and transactivates the 
ARE in the promoter region of many anti-oxidant genes 
[42]. Nrf2 seems to represent an important regulator of 
oxidative stress in sepsis [43]. For example, it has been 
reported that lipopolysaccharide-induced shock and 
polymicrobial sepsis induces early and greater mortality 
in Nrf2-defi cent mice, which is related to the lethal innate 
immune response [44]. In contrast, transgenic mice with 
a decreased rate of Nrf2 degradation showed lower 
mortality in polymicrobial sepsis [45]. Consequences of 
the down-regulation of the Nrf2 host defence mechanism 
still remain to be fully explored.
Intracellular •NO generation
Pro-oxidative and pro-infl ammatory events in the plasma 
have a strong impact on the intracellular milieu. H2O2 
causes a cascade of intracellular events resulting in the 
liberation of NF-κB from its inhibitor IκB [46]. NF-κB 
can be activated via several other pathways, as reviewed 
by MacDonald and co-workers [40]. For example, TNF-α, 
one of the primary mediators of the innate immune 
system, binds to its specifi c receptor (TNFR), which leads 
to the activation of multi-component protein kinase (IκB 
kinase), IκB phosphorylation, and NF-κB release and 
translocation into the nucleus [40] Clearly NF-κB has a 
special place in sepsis development. In an animal study 
lipopolysaccharide administration resulted in NF-κB 
activation in several organs [47]. Two diff erent research 
groups have reported that NF-κB activity is signifi cantly 
higher in septic non-survivors in comparison to controls 
and survivors and that NF-κB activity predicts sepsis-
related mortality [48,49]. Finally, encouraging results of 
clinical trials with activated protein C could be at least 
partially attributed to its ability to block the expression of 
NF-κB-regulated genes [50].
NF-κB binds to DNA to enable the initiation of the 
transcription process of a number of genes, two of them 
encoding redox-active enzymes: inducible •NO synthase 
(iNOS) [51] and cyclooxygenase (COX)-2, which gener-
ates •O2- as a by-product [52]. It is noteworthy that iNOS 
expression can be stimulated by hypoxia inducible factor-1, 
which is also activated by ROS [53]. In contrast to 
consti tutively expressed endothelial NOS, which 
produces local •NO concentrations in the nanomolar 
range, iNOS has been estimated to produce •NO in the 
micromolar range [54,55]. Th e role of iNOS expression in 
non-septic infec tions is to induce •NO-mediated vaso-
dila tation, thus enabling adequate circulation in the 
aff ected areas and normal cardiac function [56]. However, 
over-expression of iNOS in sepsis aff ects normal cellular 
functions [57]. Pertinent to such dual (patho)physio-
logical roles of iNOS in sepsis, it has been demonstrated 
in two separate studies that iNOS-defi cient animals 
exposed to endo toxin show lower cardiac output [58] but 
have improved survival [59] in comparison to control 
subjects.
Over-expression of iNOS occurs early in sepsis [54,60], 
taking place in nearly all the vital organs [61]. Patients 
with sepsis show increased •NO production and elevated 
nitrite and nitrate levels, which have been correlated with 
the severity of illness [62]. Th e negative role of iNOS in 
sepsis is also indicated by the fact that the administration 
of the iNOS substrate arginine results in a poorer out-
come in sepsis [63]. Th e mechanism that makes •NO 
production deleterious to cells seems to be related to 
protein nitrosylation and nitration, which can modulate 
the function of various enzymes and ion channels as well 
as diff erent signalling pathways [23]. In addition, •NO 
effl  ux from cells and a substantial increase in the •NO 
level in plasma may occur. •NO converts haemoglobin to 
methaemoglobin (MetHb), which leads to increased 
rigidity of red blood cells (RBCs) and RBC lysis [64]. 
Another potential cause of RBC lysis in sepsis is the 
ability of HOCl to induce membrane-pore formation in 
RBCs [65]. RBC lysis results in the release of MetHb into 
the plasma [64], refl ecting the severity of sepsis [66]. An 
increased level of free MetHb in the plasma may have 
several propagating eff ects on sepsis development: (i) it 
leads to increased availability of iron to pathogens, which 
may fuel their proliferation [67]; (ii) it has pro-infl am-
matory eff ects by stimulating interleukins (IL-6 and IL-8) 
and E-selectin [68]; and (iii) MetHb is an activator of 
NF-κB [64], which may lead to further iNOS expression, 
thus closing a •NO-generating loop (Figure 2).
Intracellular superoxide generation
Septic insult signifi cantly increases intracellular •O2- [69]. 
Th is is substantiated by the high activity of superoxide 
dismutase (SOD) in sepsis [22,27]. Th ere are several 
intra cellular •O2- generators implicated in sepsis: NADPH 
oxidase, COX-2, xanthine oxidase and the electron transfer 
chain (ETC) in mitochondria. Th e entry of ROS from the 
plasma into the cell can initiate the expression of NADPH 
oxidase and COX-2 [40,52,70]. Th e early rise in •O2- 
production in endothelial cells in sepsis is abolished by 
NADPH oxidase inhibitors [69], while the inhibition of 
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COX-2 leads to a decrease in the production of ONOO- 
(an •O2- derivative; Figure 1, reaction 3) in sepsis models 
[52,71]. At the later stages of sepsis development these 
two enzymes are accompanied by increased xanthine 
oxidase activity [72,73] and pronounced production of 
•O2- on the mitochondrial inner membrane.
Th e generation of •O2- in mitochondria is related to the 
leakage of electrons out of the respiratory chain into O2. 
Such production is intrinsic to aerobic organisms, with 
up to 2% of O2 in mammalian mitochondria reduced to 
•O2- under physiological conditions [74]. Th e production 
is pronounced if the ETC is inhibited or uncoupled [74] 
as is the case under septic conditions. It has been docu-
mented that •NO actively inhibits mitochondrial respira-
tion under sepsis-modelling conditions [75] and that 
such eff ects can be diminished by applying an iNOS inhi-
bitor [76]. Fredriksson and co-authors [22] reported a 
signifi cant decrease in the activity of complex I (the main 
site of •O2- production in the ETC [74]) in the muscles of 
septic patients. Finally, a very recent study noted ETC 
un coupling in severe sepsis and septic shock, the res-
ponse being most pronounced in non-survivors [77]. In 
mitochondria, •O2- is dismutated by MnSOD to H2O2, 
which enters the cytosol to close the redox loop (Figure 2).
Figure 2. The ‘sepsis redox cycle’. Pathogens activate the immune system, which excessively generates H2O2 and HOCl. Inside the cell, H2O2 
provokes the activation of NF-κB (also activated by cytokines and methaemoglobin (MetHb)), which stimulates the expression of inducible nitric 
oxide synthase (iNOS). These events result in the production of •NO in micromolar concentrations. •NO provokes inhibition of the electron transfer 
chain (ETC), which leads to increased production of •O2
-. In the reaction between •NO and •O2
-, ONOO- is produced, which is then protonated to 
form peroxynitrous acid (ONOOH), which in turn spontaneously decomposes to two highly reactive species - •OH and •NO2. These species damage 
mitochondria and in cooperation with ETC inhibition provoke mitochondrial dysfunction resulting in a fall in ATP. Superoxide is also produced 
in the cytosol via increased activities of three enzymes: NADPH oxidase, cyclooxygenase (COX)-2 and xanthine oxidase (XO). Indirectly, via DNA 
damage, poly (ADP-ribose) polymerase (PARP) activation and NAD+ consumption, ONOO- promotes the production of •O2
- on complex I in the ETC, 
which depends on the NADH/NAD+ ratio. Superoxide is dismutated in mitochondria by manganese superoxide dismutase (MnSOD) to H2O2, which 
closes two positive feedback redox loops. Intracellular •NO overproduction leads to •NO leakage into the plasma. There •NO provokes red blood 
cell (RBC) lysis while HOCH provokes pore formation in RBC membranes, thus freeing MetHb and increasing iron availability, which fuels pathogen 
proliferation. MetHb provokes the activation of NF-κB, thus closing the •NO-generating loop. The plus (+) and minus (-) symbols represent positive 
and negative eff ects on concentration, gene expression or activity, respectively. TNFR, TNF receptor.
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Peroxynitrite production and its eff ects
Th e interaction between •NO and •O2- plays a funda-
mental role in cell and organ failure [78]. Superoxide 
reacts with •NO at a slightly faster rate than with SOD so 
when the level of •NO is in the high nanomolar or 
micromolar range •NO may outcompete SOD and react 
with •O2- to generate ONOO- [79] (Figure 1, reaction 3), 
which is capable of inhibiting enzyme and membrane 
functions [23]. In particular, ONOO- is responsible for 
decreased activity of the H2O2-removing enzyme gluta-
thione peroxidase in sepsis [80]. Th e relevance of this 
interaction in sepsis is demonstrated by the fact that sele-
nium, which is crucial for glutathione peroxidase meta bo-
lism, shows clinical benefi ts in sepsis treatment [25,80].
Th e most important eff ects of ONOO- in sepsis are 
exerted indirectly on mitochondria. It causes DNA single-
strand breakage in the nucleus, which signals poly(ADP-
ribose) polymerase (PARP) to be activated. PARP 
catalyses the cleavage of NAD+, which leads to a decrease 
in the NAD+ level and to an increase in the NADH/NAD+ 
ratio [54,81]. A high NADH/NAD+ ratio is known to raise 
•O2- production on the mitochondrial complex I [74]. It 
appears that the ONOO--provoked increase in •O2- pro-
duc tion on complex I represents the third major event in 
sepsis following the immune system-generated oxidative 
burst and iNOS over-expression. In vitro studies have 
shown that PARP activation causes energy depletion and 
cellular injury, while pharmaco logical inhibition of PARP 
improves the response of mitochondria to ONOO- 
challenge [81]. In addition, PARP inhibitors have been 
shown to diminish sepsis-provoked mitochondrial impair-
ment [56]. Th e impor tance of the ONOO-/PARP/NAD+/
complex I sequence of events in sepsis is illustrated by 
the fact that PARP-defi cient mice with sepsis show 
improved survival, while the administration of PARP 
inhibitors is benefi cial in a porcine model of sepsis 
[82,83]. Finally, Khan and co-workers [84] have shown 
that the application of liposomal NAD+ on immuno-
stimulated cells (modelling sepsis), lead ing to a decreased 
NADH/NAD+ ratio, prevents dimin ished consumption of 
O2 provoked by ONOO-.
As in the case of •NO-promoted •O2- production in 
mito chondria, ONOO--provoked generation of •O2- results 
in increased mitochondrial H2O2, which leaks from 
mitochondria to further promote NF-κB activation, thus 
closing another redox loop (Figure 2). In line with this, 
application of the ONOO--decomposition catalyst FeTPPS 
has been reported to reduce NF-κB activation in endo-
toxaemic mice [85].
Mitochondrial dysfunction
Mitochondria are specifi cally targeted by highly reactive 
products of ONOO- decomposition - •OH and •NO2 [23] 
(Figure 1, reaction 4). Th e hydroxyl radical non-selec tively 
damages membranes, proteins and DNA [24] while •NO2 
binds to proteins leading to increased susceptibility to 
protease activity [23]. Pertinent to this, research regard-
ing mitochondrial structure after lipopolysac charide 
insult revealed oxidative stress and pronounced 
mitochondrial DNA damage [16,20]. In combination 
with ETC inhibition, oxidative modifi cations lead to 
mito chondrial dysfunction, which is intimately linked to 
a depleted cellular ATP pool and an energy defi cit 
charac teristic of sepsis (Table 3).
Dysfunctional mitochondria show increased suscepti-
bility to mitoptosis. Morphological changes characteristic 
of mitoptosis have been documented in a feline model of 
acute endotoxaemia [86], while a decrease in mito chon-
drial content has been observed in patients with pro-
longed septic conditions [22]. A lower number of mito-
chondria may further compromise energy balance. 
Together, a fall in ATP concentration and oxidative stress 
exerted on mitochondrial metabolites lead to mitochon-
drial permeability transition pore opening with eventual 
organelle swelling and cytochrome c release. Once in the 
cytoplasm, cytochrome c can bind to apoptotic protease 
activating factor 1 (APAF-1) and thus activate caspase-9, 
which in turn activates caspase-3 and -7, culminating in 
apoptosis in some cell types. Anti-oxidant treatment can 
prevent mitochondrial swelling and cytochrome c 
release, pinpointing the role of ROS in mitochondrial 
dysfunction [87]. Mitochondrial dysfunc tion represents 
the fourth and fi nal major redox event in the pathogenesis 
of sepsis.
Patients typically die of sepsis days to weeks after the 
onset of the initial infection and in some cases even after 
the original infection has been eradicated [1,2]. Interest-
ingly 10 to 40% of sepsis patients show negative cultures 
[1,2]. At the later stages of sepsis the immune system is in 
a hypoactive mode. Th erefore, the plasma oxidative burst 
can no longer be directly responsible for cell/organ 
dysfunction [7]. Th ese facts imply that infection could, 
under specifi c conditions, activate a self-sustaining and 
self-promoting redox cycle. Instead of shutting down 
upon pathogen eradication or in the immune hypoactive 
stage the ‘sepsis redox cycle’ continues to drain energy 
and prevents normal function from being re-established 
due to several positive feedback loops (Figure 2), even 
when there is no further infl ow of reactive species from 
plasma. It is important to note that in the ‘sepsis redox 
cycle’ H2O2 crosses both cellular and mitochondrial mem-
branes. Th is transport is facilitated by aquaporin-8 [88]. 
Interestingly, aquaporin-8 is down-regulated in sepsis 
[89], which may be a mechanism of defence targeted at 
stopping or slowing down the cycle. Th e pathophysio-
logical redox profi le of one cell can spill over to surround-
ing tissue, due to the ability of H2O2 and •NO to cross 
membranes, thus leading to organ failure.
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Polymorphisms of redox-relevant genes and sepsis
Th e question why the activation of the immune system in 
some patients leads to sepsis and in others does not 
remains unresolved. On the basis of studies in identical 
twins genetic factors have been implicated in the deter-
mination of susceptibility to death from infections [90]. It 
seems that specifi c gene polymorphisms of some redox-
active enzymes are more frequent in patients with sepsis 
and other related conditions in comparison to the general 
population (Table 4). However, the exact role of gene poly-
morphisms in sepsis susceptibility and sepsis develop-
ment, progression and outcome remains to be further 
elucidated.
Redox therapy in sepsis
Sepsis is treated by controlling the source of infection, 
administering antimicrobial therapy, assuring hemo-
dynamic support with fl uid resuscitation and vasopressor 
drugs, inducing sedation or analgesia as needed and by 
other supportive therapies [91]. Despite these inter-
ventions, about one-third of all septic patients die before 
leaving hospital [1,2]. Th erefore, the development of 
additional treatment approaches, such as anti-oxidative 
therapy, is a research topic of urgent priority.
Although many promising results have been obtained 
from animal models, believable benefi t from anti-oxidant 
application in sepsis has rarely been translated into 
success in human clinical trials [92]. Th is may be 
explained by several reasons. Animal models of sepsis do 
not completely recapitulate the human disease or involve 
identical care delivered to human sepsis patients [93-95]. 
Th e onset and progression of sepsis to multi-organ failure 
occurs over days to weeks whereas in most animal 
models these processes are much faster, occurring within 
hours to days. Animal models of sepsis almost exclusively 
use young animals, which mimic the physiology of a 
young human. Th e pitfall here is that epidemiologic 
studies show that the older human population is more 
susceptible to sepsis. Moreover, in contrast to animal 
models, patients with sepsis commonly have co-mor-
bidities [95]. Finally, models and clinical sepsis show very 
diff erent cytokine dynamics [93,94]. It should be stressed 
that therapeutic studies on animals sometimes involve 
the application of high doses of anti-oxidants exceeding 
recom mended human allowances that clinical researchers 
are reluctant to use in trials. In addition, animal studies 
frequently employ early application of therapy (or pre-
treatment), which is often not the case with clinical 
sepsis. Some clinical trials do not take into account all the 
main principles of anti-oxidative therapy. Halliwell and 
Gutteridge [23] made a list of questions that generally 
should be answered preceding the use of an anti-oxidant 
in humans: (i) Is it non-toxic? (ii) Which biomolecules 
will the anti-oxidant protect, and are such molecules 
implicated in the pathogenesis of the disease? (iii) How 
does the anti-oxidant work - by scavenging reactive 
species, increasing endogenous defence or by repairing 
the damage? (iv) Can the anti-oxidant-derived products 
cause damage? (v) Does the anti-oxidant interfere with 
redox signalling? Kohen and Nyska [96] sublimed the 
principles of anti-oxidant therapy as follows: ‘Taking into 
consideration the high reactivity of ROS, their short life 
span, their continuous production in close proximity to 
biological targets and their ability to be modifi ed into 
other more reactive species, one realises that, in order to 
cope with these deleterious metabolites, the anti-oxidant 
should be administered to the body continuously, in high 
concentrations and targeted to the biological site suscep-
tible to oxidative damage.’ Pertinent to this and the 
mechanism proposed here, it is clear that a redox 
approach in sepsis treatment should be targeted at the 
specifi c steps in the pathogenesis. For example, very 
promising eff ects of therapies targeting dysfunc tional 
mitochondria have been reviewed recently by Dare and 
colleagues [16] and Galley [20].
Targeted delivery of anti-oxidants into intracellular 
space is limited by mechanisms regulating the level of 
reducing agents in order to maintain normal functioning 
of signalling pathways that involve reactive species [97]. 
Th erefore, even if long-term supplementation raises blood 
anti-oxidants, it will have a limited eff ect on intracellular 
levels or redox status [97]. Hence, the majority of 
Table 3. The level of ATP in sepsis
Subjects Results Reference
Critically ill septic patients and healthy subjects undergoing elective surgery ATP (nmol/mg dry weight) in skeletal muscle biopsies:  [21]
    Controls (8): 12.5 (9.7 to 13.7)
    Survivors (12):15.8 (12.1 to 18.6)
    Non-survivors (9): 7.6 (6.6 to 10.0) (P < 0.001)
Human umbilical vein endothelial cells incubated with healthy or septic sera ATP (nmol/L) in the cells exposed to the serum of:  [76]
    Controls: 13.5 ± 1.9
    Septic shock patients: 6.7 ± 1.2 (P < 0.01)
Murine model of endotoxaemia (LPS-induced) ATP (μmol/g wet weight) in liver:  [122]
    Controls: 3.51 ± 0.21
    Endotoxaemic: 3.00 ± 0.13 (P < 0.05)
LPS, lipopolysaccharide.
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anti-oxidants perform their actions predominantly in 
plasma, which may have benefi cial eff ects during the 
hyper-infl ammatory stage of sepsis but are ineff ective 
against the self-sustaining ‘sepsis redox cycle’ taking 
place inside the cell. Th is raises the question of how to 
overcome refractory mechanisms and help the organism 
to fi ght intracellular oxidative stress against its own ‘will’. 
In other words, in conditions related to intracellular 
oxidative stress, such as sepsis, reducing agents targeted 
to intra cellular space and capable of accumulating inside 
the cell are needed.
Potential candidates for such an approach are fructose 
1,6-(bis)phosphate and ethyl pyruvate, which act as both 
antioxidants and energy molecules [98,99], and orga-
nisms in times of crisis will not reject energy supplies. 
Th ese compounds have already shown positive eff ects in 
sepsis models [100-103], but are yet to be studied in 
clinical trials. Molecular hydrogen that reacts directly 
with ROS should also be capable of overcoming the 
refractory response. Recently, Xie and co-workers [104] 
reported that H2 inhalation signifi cantly improved the 
survival rate of septic mice in a concentration- and time-
dependent manner.
An alternative anti-oxidative approach is to suppress 
ROS production in mitochondria. It has been shown that 
maintenance of glucose in blood within the range 4.4 to 
6.1 mM, instead of the normally higher range of 10.0 to 
11.1 mM, leads to a decrease in mortality by more than 
10% [105]. We propose that decreased availability of 
glucose could exert positive eff ects in sepsis by prevent-
ing the production of •O2- on mitochondrial complex I. A 
lower level of glucose leads to decreased generation of 
NADH and hence to a decrease in the NADH/NAD+ 
ratio. Another way to decrease the NADH/NAD+ ratio is 
Table 4. Polymorphisms of genes involved in redox regulation that are implicated in sepsis and related conditions
Gene Polymorphism Eff ect of polymorphism Population Genotypes Reference
p22-PHOX (NADPH 
oxidase subunit)
C242T T allele is associated with 
higher plasma levels of 
nitrotyrosine (circulating 
biomarker of •O2
- and •NO 
generation)
Patients with acute renal 
failure (200)
T-allele carrier state was associated 
with 2.1-fold higher odds for dialysis 
requirement or hospital death (P < 0.01)
[123]
MNSOD Ala9Val Valine variant is associated 
with decreased intra-
mitochondrial transport of 
MnSOD
Healthy subjects (100) and 
patients with sepsis (40)
A/A: 20% (frequency in control group) and 
27.5% (in sepsis)
V/V: 36% and 10%
A/V: 44% and 62.5%
[124]
eNOS G894T T allele is related to low levels 
of eNOS activity
Patients with Escherichia coli 
bacteraemia (42)
Carriage of the T allele was associated 
with low mean arterial pressure and high 
Sequential Organ Failure Assessment score
[125]
MPO (gene 
promoter)
G-129A A allele causes loss of 
transcriptional factor binding 
site and lower amount of MPO 
in cytoplasmatic granules
Patients that underwent 
chemotherapy (136) or 
autologous stem cell 
transplantation (113)
Chemotherapy:
   GG: 11% developed sepsis
   GA: 17% developed sepsis
ASCT:
   GG: 7% developed sepsis
   GA: 25% developed sepsis
[126]
NRF2 (gene 
promoter)
C-617A A allele presents less 
transcriptional activity than 
C allele
Humans with major trauma 
(164)
Carriage of the A allele was related to a 
greater risk of acute lung injury (P = 0.021) 
[127]
HMOX1 (gene 
promoter)
(GT)n Longer (GT)n repeats in 
the HMOX1 promoter are 
associated with higher plasma 
HO-1 levels
ICU patients who developed 
(437) or did not develop 
(1014) acute respiratory 
distress syndrome 
Longer (GT)n repeats are associated 
with reduced acute respiratory distress 
syndrome risk
[128]
TNF TNF1 and TNF2 
allele
TNF2 is associated with 
higher levels of inducible and 
constitutional TNF
Critically ill infected patients 
(112)
TNF2 frequency:
   General population: 5% 
   Studied group: 12% (P < 0.01)
Overall mortality:
   TNF1/TNF1: 48%
   TNF1/TNF2: 62%
The frequency of septic shock:
   TNF1/TNF1: 34%
   TNF1/TNF2: 50%
Mortality in septic shock patients:
   TNF1/TNF1: 62%
   TNF1/TNF2: 92% (P < 0.05)
[129]
HIF-1α C85T T variant presents more 
transcriptional activity
Patients with acute kidney 
injury (241) 
T-allele carriers had signifi cantly higher 
odds for in-hospital death (P < 0.001)
[130]
eNOS, endothelial NOS; HIF, hypoxia inducible factor; HO-1, haem oxygenase (haem degrading enzyme); MnSOD, manganese superoxide dismutase; MPO, 
myeloperoxidase (HOCl generator).
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to apply liposomal NAD+, which has been shown to 
prevent diminished O2 consumption in mitochondria 
under septic conditions [84]. As an alternative to feeding 
complex I, which represents a point of electron leakage 
and •O2- production, mitochondrial complex II could be 
supplemented with succinate in order to bypass •O2- pro-
duction on complex I and in parallel to maintain normal 
energy metabolism. Several studies have confi rmed 
positive eff ects of succinate in sepsis [106-108].
Pertinent to the important role of iNOS and •NO in 
sepsis-related cell/organ dysfunction, therapeutic strate-
gies capable of decreasing the level of •NO could be 
benefi cial in sepsis. Th e supplementation of selective 
iNOS inhibitors, such as aminoguanide, L-NAME and L-
N6-(1-imminoethyl)lysine, has had positive eff ects in 
diff erent sepsis models [109-113]. It is interesting that a 
clinical trial of the non-selective NOS inhibitor L-
NMMA in patients with septic shock was terminated 
early because of increased mortality. Such an adverse 
eff ect of high-dose L-NMMA may have resulted from the 
inhibition of endothelial NOS, whose activity is essential 
for microvascular homeostasis [114]. In addition to iNOS 
inhibition, •NO excess can be tackled using •NO 
scavengers. For example, diethyldithiocarbamate (DDC) 
demonstrates positive eff ects in septic shock mice, 
partially due to the ability of the iron-DDC complex to 
sequester •NO [115].
Conclusions
Organ failure in sepsis is provoked by cellular dysfunc tion, 
a process related to pro-oxidative conditions and 
dysfunctional mitochondria. Th e oxidative burst perfor-
med by the innate immune system is ‘transferred’ from the 
plasma into the cell, where it activates the production of 
ROS and RNS, resulting in non-physiological redox 
conditions, disturbed redox signalling, oxidative damage 
of diverse molecules and cellular structures and energy 
depletion. Th ese events are interconnected in a self-
sustaining and self-promoting pathological process named 
here as the ‘sepsis redox cycle’, which may result in the 
total loss of cellular function. Redox therapies targeting 
specifi c steps of the ‘sepsis redox cycle’ have shown some 
very promising results for sepsis treatment, but require 
further clinical evaluation. Although it is obvious that 
sepsis represents a multi-factorial patho physiology, studies 
investigating the eff ects of multi-target therapies are still 
scarce. We believe that instead of looking for a single 
‘magic bullet’ for sepsis treatment, a multi-component 
‘magic bullets’ therapeutic approach combining diff erent 
redox agents capable of suppressing specifi c steps in the 
pathogenesis of sepsis is clearly the way forward.
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